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Abstract: The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific 
antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for 
BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer 
and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivided into four molecular subtypes, 
luminal A, luminal B, HER-2 or TNBC, according to the results of ER, PR, HER-2, Ki-67 immunohistochemistry and 
HER-2 FISH. In TNBC cases, additional immunohistochemical stain for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, 
E-cadherin, AR, GGT-1, STAT1, and interleukin-8 were performed. TNBC cases were then further subcategorized as 
follows: basal-like type (CK5/6 positive and/or EGFR positive), molecular apocrine type (AR positive and/or GGT-1 
positive), claudin low type (claudin 3, claudin 4, claudin 7 negative and E-cadherin negative), immune related type 
(stromal STAT1 positive and IL-8 negative), mixed type (cases consisting of two or more mixed components), and null 
type (cases that cannot be categorized in any of abovementioned types). In 230 breast cancer, 30 (13.0%) cases 
showed positivity for BRAF V600E mutation specific antibody, and 17 (7.4%) showed nuclear expression. The nucle-
ar BRAF V600E positivity was associated with ER negativity (P=0.003), PR negativity (P=0.031) and TNBC subtype 
(P=0.009). In 132 cases of TNBC, 4 (3.0%) cases were positive for BRAF V600E mutation specific antibody, and 10 
(7.6%) cases showed nuclear expression. BRAF V600E positivity was most frequently found in the null type, followed 
by mixed type and basal-like type, and was not found in other subtypes. In TNBC, the nuclear BRAF V600E positivity 
was associated with lower histological grade (P=0.012). BRAF V600E status did not correlate with the prognosis of 
breast cancers and TNBC. In conclusion, positivity for BRAF V600E mutation specific antibody was noted in a frac-
tion of breast cancer and TNBC, suggesting the presence of BRAF mutation. BRAF mutation did not have association 
with clinicopathologic factors of breast cancer.
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Introduction
BRAF is a member of Raf kinase family pro-
teins, weighing 75-100 kDa, and it is the most 
important activator of MEK kinase in Ras-Raf-
MEK-ERK pathway [1, 2]. In certain tumors, 
Ras-Raf-MEK-ERK pathway is abnormally acti-
vated; the BRAF mutation is a typical cause of 
aberrant ERK signaling [3]. BRAF mutation was 
first reported in 2002, and in 90% of them, a 
missense mutation occurs at nucleotide 1796, 
and this results in valine to glutamic acid sub-
stitution at codon 599 (V599E; later renamed 
to V600E due to nomenclature change [4]. 
BRAF V600E mutation is reported to be found 
in various neoplasms, and the reported preva-
lence in tumors are as follows; malignant mela-
noma (40-70%), colorectal carcinoma (5-22%), 
thyroid papillary carcinoma (36-53%), glioma 
(11%), ovary serous carcinoma (30%), lung ade-
nocarcinoma (4%) and hairy cell leukemia 
(100%) [5]. The gold standard method for 
detecting BRAF mutation is the Sanger sequenc-
ing method, but the test is expensive and it 
requires expensive equipment. To overcome 
these drawbacks, immunohistochemistry (IHC) 
method using BRAF V600E mutation specific 
antibody was introduced [6]. In a study per-
formed with MSI-H colorectal carcinomas, this 
method showed a high concordance rate 
(98.9%) with Sanger sequencing method, and 
100% of sensitivity and 98.8% of specificity [7], 
revealing IHC by BRAF V600E mutation specific 
antibody is an effective surrogate method for 
evaluating BRAF V600E mutation.
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Breast cancer is a neoplasm that is well known 
to have genetic aberration and genetic hetero-
geneity [8]. In previous studies, in about 10% of 
breast cancer cell lines had BRAF mutation [9], 
suggesting the possible presence of BRAF 
mutation in breast cancer tissues. A few stud-
ies on BRAF mutations in breast cancer tissues 
have been performed so far, using sequencing 
methods [10, 11], but studies that used BRAF 
V600E mutation specific antibody are rare. The 
aim of this study is to investigate the BRAF 
mutation status using IHC with BRAF V600E 
mutation specific antibody, and its clinical 
implications.
Materials and methods
Patient selection and histologic evaluation
In this study, two groups of breast cancers are 
involved. The first group involves the patients 
who were diagnosed with invasive ductal carci-
noma (IDC), NOS from January, 2006 to 
December, 2006 at Severance hospital. In the 
second group, patients who were diagnosed 
with triple negative breast cancer (TNBC), from 
January 2000 to December 2005 at Severance 
hospital were enrolled. Patients who had pre-
operative chemotherapy or hormone therapy 
were excluded. This study was approved by the 
Institutional Review Board of Yonsei University 
Severance Hospital. IRB exempted the informed 
consent from patients. All cases were review- 
ed by a breast pathologist (Koo JS) with 
Hematoxylin & Eosin (H&E)-stained slides. 
Histological grade was assessed using the 
Nottingham grading system [12]. Clini- 
copathologic parameters evaluated in each 
case included patient age at initial diagnosis, 
lymph node metastasis, tumor recurrence, and 
patient survival.
The tumor stroma of IDC were subcategorized 
into four types as following; 1) desmoplastic 
type: in cases the tumor stroma consists of cel-
lular fibroblast/myofibroblast proliferation, 2) 
sclerotic type: in cases fibrotic collagenous 
component predominates with little cancer cell 
component, 3) pauci type; in cases with no stro-
mal reaction or in cases with normal breast 
stroma, 4) inflammatory type: in cases when 
the inflammatory cells such as lymphocyte pre-
dominates the tumor stroma.
In TNBC, following histologic features were eval-
uated; apocrine histology, central fibrotic zone, 
and lymphocyte infiltration. The apocrine histol-
ogy was defined by abundant granular eosino-
philic cytoplasm, cytoplasmic vacuolization, 
and vesicular nuclei with prominent nucleoli in 
more than 10% of tumor cells.
Table 1. Source, clone, and dilution of used antibodies
Antibody Clone Dilution Company
BRAF V600E mutation related
    BRAF V600E VE1 1:50 Spring Bioscience, Pleasanton, CA, USA
Molecular subtype related
    ER SP1 1:100 Thermo Scientific, San Diego, CA, USA
    PR PgR 1:50 DAKO, Glostrup, Denmark
    HER-2 Polyclonal 1:1500 DAKO, Glostrup, Denmark
    Ki-67 MIB-1 1:150 DAKO, Glostrup, Denmark
TNBC molecular subtype related
    CK5/6 D5/16B4 1:50 DAKO, Glostrup, Denmark
    EGFR EGFR.25 1:50 Novocastra, Newcastle, UK
    AR AR441 1:50 DAKO, Glostrup, Denmark
    GGT-1 IgG2A 1:50 Abcam, Cambridge, UK
    Claudin 3 Polyclonal 1:50 Abcam, Cambridge, UK
    Claudin 4 Polyclonal 1:100 Abcam, Cambridge, UK
    Claudin 7 Polyclonal 1:100 Abcam, Cambridge, UK
    E-cadherin 36B5 1:100 Novocastra, Newcastle, UK
    STAT1 Polyclonal 1:100 Abcam, Cambridge, UK
    Interleukin-8 807 1:50 Abcam, Cambridge, UK
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Tissue microarray
A representative area showing tumor and tumor 
stroma was selected on an H&E-stained slide, 
and a corresponding spot was marked on the 
surface of the paraffin block. Using a biopsy 
needle, the selected area was punched out, 
and a 3-mm tissue core was transferred to a 6 
× 5 recipient block. Two tissue cores of invasive 
tumor were extracted to minimize extraction 
bias. Each tissue core was assigned a unique 
tissue microarray location number that was 
linked to a database containing other clinico-
pathologic data. 
Immunohistochemistry 
Antibodies used for IHC are listed in Table 1. All 
IHC was performed with formalin-fixed, paraf-
fin-embedded tissue sections using an auto-
matic IHC staining device (Benchmark XT, 
Ventana Medical System, Tucson, AZ, USA). 
Briefly, 5-µm-thick formaldehyde fixed paraffin-
embedded tissue sections were transferred 
onto adhesive slides and dried at 62°C for 30 
minutes. Standard heat epitope retrieval was 
performed for 30 minutes in ethylene diamine 
tetraacetic acid, pH 8.0, in the autostainer. The 
samples were then incubated with primary anti-
Table 2. Clinicopathologic characteristics of patients according to breast cancer molecular subtypes










    ≤50 131 (57.0) 66 (57.4) 39 (68.4) 7 (46.7) 19 (44.2)
    >50 99 (43.0) 49 (42.6) 18 (31.6) 8 (53.3) 24 (55.8)
Histologic grade <0.001
    I/II 163 (70.9) 105 (91.3) 36 (63.2) 8 (53.3) 14 (32.6)
    III 67 (29.1) 10 (8.7) 21 (36.8) 7 (46.7) 29 (67.4)
Tumor stage 0.112
    T1 146 (63.5) 80 (69.6) 35 (61.4) 10 (66.7) 21 (48.8)
    T2/T3 84 (36.5) 35 (30.4) 22 (38.6) 5 (33.3) 22 (51.2)
Nodal metastasis 0.555
    Absent 147 (63.9) 69 (60.0) 37 (64.9) 10 (66.7) 31 (72.1)
    Present 83 (36.1) 46 (40.0) 20 (35.1) 5 (33.3) 12 (27.9)
Estrogen receptor status <0.001
    Negative 63 (27.4) 2 (1.7) 3 (5.3) 15 (100.0) 43 (100.0)
    Positive 167 (72.6) 113 (98.3) 54 (94.7) 0 (0.0) 0 (0.0)
Progesterone receptor status <0.001
    Negative 80 (34.8) 10 (8.7) 12 (21.1) 15 (100.0) 43 (100.0)
    Positive 150 (65.2) 105 (91.3) 45 (78.9) 0 (0.0) 0 (0.0)
HER-2 status <0.001
    Negative 185 (80.4) 115 (100.0) 27 (47.4) 0 (0.0) 43 (100.0)
    Positive 45 (19.6) 0 (0.0) 30 (52.6) 15 (100.0) 0 (0.0)
Ki-67 LI (%) <0.001
    ≤14 144 (62.6) 115 (100.0) 18 (31.6) 6 (40.0) 5 (11.6)
    >14 86 (37.4) 0 (0.0) 39 (68.4) 9 (60.0) 38 (88.4)
Stromal type 0.007
    Desmoplastic 86 (37.4) 40 (34.8) 28 (49.1) 6 (40.0) 12 (27.9)
    Lymphocytic 16 (7.0) 3 (2.6) 3 (5.3) 1 (6.7) 9 (20.9)
    Pauci 9 (3.9) 4 (3.5) 3 (5.3) 0 (0.0) 2 (4.7)
    Sclerotic 119 (51.7) 68 (59.1) 23 (40.4) 8 (53.3) 20 (46.5)
    Tumor recurrence 11 (4.8) 4 (3.5) 2 (3.5) 1 (6.7) 4 (9.3) 0.444
    No. of patient deaths 18 (7.8) 6 (5.2) 3 (5.3) 2 (13.3) 7 (16.3) 0.090
Note: TNBC, triple negative breast cancer.
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bodies. After incubation with primary antibod-
ies, The sections were subsequently incubated 
with biotinylated anti-mouse immunoglobulins, 
peroxidase-labeled streptavidin (LSAB kit, 
DakoCytomation), and 3,30-diaminobenzidine. 
Negative control samples were processed 
without the primary antibody. Slides were coun-
terstained with Harris hematoxylin. Positive 
control tissue was used as per the manufac-
turer’s recommendation. Slides were counter-
stained with Harris hematoxylin.
Interpretation of immunohistochemical stain-
ing
All immunohistochemical markers were acce- 
ssed by light microscopy. A cut-off value of 1% 
or more positively stained nuclei was used 
to define ER and PR positivity [13]. HER-2 stain-
ing was analyzed according to the American 
Society of Clinical Oncology (ASCO)/College of 
American Pathologists (CAP) guidelines using 
the following categories: 0 = no immunostain-
ing; 1+ = weak incomplete membranous stain-
ing, less than 10% of tumor cells; 2+ = com-
plete membranous staining, either uniform or 
weak in at least 10% of tumor cells; and 3+ = 
uniform intense membranous staining in at 
least 30% of tumor cells [14]. HER-2 immunos-
taining was considered positive when strong 
(3+) membranous staining was observed, 
whereas cases with 0 to 1+ were regarded as 
negative. Cases showing 2+ HER-2 expression 
were evaluated for HER-2 amplification by 
fluorescent in situ hybridization (FISH). Ki-67 
labeling index (LI) was defined as the percent-
age of nuclear-positive cells among the tumor 
cells.
Immunohistochemical markers for TNBC mo- 
lecular subtype were accessed by light micros-
copy. The stained slides were evaluated semi 
quantitatively [15]. Tumor and stromal cell 
staining were assessed as 0: negative or weak 
immunostaining in <1% of the tumor/stroma, 1: 
focal expression in 1-10% of tumor/stroma, 2: 
positive in 11%-50% of tumor/stroma, and 3: 
positive in 51%-100% of tumor/stroma. The 
evaluation was performed throughout the 
whole area of the tumor, and score 0 was 
regarded negative, and 1 or more was recorded 
positive. Cases with 20% or more positive 
tumor cells were recorded BRAF V600E posi-
tive [16].
Tumor phenotype classification
In this study, we classified breast cancer phe-
notypes according to the IHC results for ER, PR, 
HER-2, Ki-67 and FISH results for HER-2 as fol-
lows [17]: luminal A type, ER or/and PR positive, 
HER-2 negative and Ki-67 LI <14%; Luminal B 
type, (HER-2 negative) ER or/and PR positive, 
HER-2 negative and Ki-67 LI ≥14%; (HER-2 pos-
itive) ER or/and PR positive and HER-2 overex-
pressed or/and amplified; HER-2 overexpres-
sion type, ER and PR negative and HER-2 over-
expressed or/and amplified; TNBC type: ER, PR, 
and HER-2 negative. 
According to the results of IHCs, TNBC were 
sub-classified as below [15]; basal-like type 
Figure 1. Expression of BRAF V600E mutation specific antibody in immunohistochemistry according to the molecu-
lar subtype in breast cancer. In luminal A and HER 2 type, homogenous and diffuse cytoplasmic expression is noted, 
while triple negative breast cancer shows nuclear expression.
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(CK5/6 positive and/or EGFR positive), molecu-
lar apocrine type (AR positive and/or GGT-1 
positive), claudin low type (claudin 3, claudin 4, 
claudin 7 negative and E-cadherin negative), 
immune related type (stromal STAT1 positive 
and IL-8 negative), mixed type (cases consist-
ing of two or more mixed components), and null 
type (cases that cannot be categorized in any of 
abovementioned types). 
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). For 
determination of statistical significance, 
Student’s t and Fisher’s exact tests were used 
for continuous and categorical variables, 
respectively. In the case of analyzing data with 
multiple comparisons, a corrected p-value with 
Table 3. Clinicopathologic characteristics of patients according to the status of BRAF V600E immuno-
histochemistry
Parameter









Age (years) 0.409 0.872
    ≤50 116 (58.0) 15 (50.0) 121 (56.8) 10 (58.8)
    >50 84 (42.0) 15 (50.0) 92 (43.2) 7 (41.2)
Histologic grade 0.238 0.979
    I/II 139 (69.5) 24 (80.0) 151 (70.9) 12 (70.6)
    III 61 (30.5) 6 (20.0) 62 (29.1) 5 (29.4)
Tumor stage 0.426 0.348
    T1 125 (62.5) 21 (70.0) 137 (64.3) 9 (52.9)
    T2/T3 75 (37.5) 9 (30.0) 76 (35.7) 8 (47.1)
Nodal metastasis 0.632 0.263
    Absent 129 (64.5) 18 (60.0) 134 (62.9) 13 (76.5)
    Present 71 (35.5) 12 (40.0) 79 (37.1) 4 (23.5)
Estrogen receptor status 0.593 0.003
    Negative 56 (28.0) 7 (23.3) 53 (24.9) 10 (58.8)
    Positive 144 (72.0) 23 (76.7) 160 (75.1) 7 (41.2)
Progesterone receptor status 0.858 0.031
    Negative 70 (35.0) 10 (33.3) 70 (32.9) 10 (58.8)
    Positive 130 (65.0) 20 (66.7) 143 (67.1) 7 (41.2)
HER-2 status 0.949 0.669
    Negative 161 (80.5) 24 (80.0) 172 (80.8) 13 (76.5)
    Positive 39 (19.5) 6 (20.0) 41 (19.2) 4 (23.5)
Ki-67 LI (%) 0.751 0.169
    ≤14 126 (63.0) 18 (60.0) 136 (63.8) 8 (47.1)
    >14 74 (37.0) 12 (40.0) 77 (36.2) 9 (52.9)
Stromal type 0.705 0.412
    Desmoplastic 74 (37.0) 12 (40.0) 82 (38.5) 4 (23.5)
    Lymphocytic 15 (7.5) 1 (3.3) 14 (6.6) 2 (11.8)
    Pauci 7 (3.5) 2 (6.7) 9 (4.2) 0 (0.0)
    Sclerotic 104 (52.0) 15 (50.0) 108 (50.7) 11 (64.7)
Molecular subtype 0.266 0.009
    Luminal A 99 (49.5) 16 (53.3) 110 (51.6) 5 (29.4)
    Luminal B 50 (25.0) 7 (23.3) 55 (25.8) 2 (11.8)
    HER-2 11 (5.5) 4 (13.3) 13 (6.1) 2 (11.8)
    TNBC 40 (20.0) 3 (10.0) 35 (16.4) 8 (47.1)
Note: TNBC, triple negative breast cancer.
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Table 4. Clinicopathologic characteristics of patients according to triple negative breast cancer phenotype














    ≤50 77 (58.3) 36 (65.5) 5 (45.5) 4 (50.0) 3 (50.0) 16 (55.2) 13 (56.5)
    >50 55 (41.7) 19 (34.5) 6 (54.5) 4 (50.0) 3 (50.0) 13 (44.8) 10 (43.5)
Histologic grade 0.586
    I/II 42 (31.8) 17 (30.9) 6 (54.5) 3 (37.5) 1 (16.7) 9 (31.0) 9 (26.1)
    III 90 (68.2) 38 (69.1) 5 (45.5) 5 (62.5) 5 (83.3) 20 (69.0) 17 (73.9)
Tumor stage 0.719
    T1 50 (37.9) 24 (43.6) 5 (45.5) 3 (37.5) 1 (16.7) 10 (34.5) 7 (30.4)
    T2/T3 82 (62.1) 31 (56.4) 6 (54.5) 5 (62.5) 5 (83.3) 19 (65.5) 16 (69.6)
Nodal metastasis 0.459
    No 86 (65.2) 40 (72.7) 6 (54.5) 5 (62.5) 5 (83.3) 18 (62.1) 12 (52.2)
    Yes 46 (34.8) 15 (27.3) 5 (45.5) 3 (37.5) 1 (16.7) 11 (37.9) 11 (47.8)
Central acellular zone 0.224
    No  101 (76.5) 38 (69.1) 11 (100.0) 6 (75.0) 6 (100.0) 22 (75.9) 18 (78.3)
    Yes  31 (23.5) 17 (30.9) 0 (0.0) 2 (25.0) 0 (0.0) 7 (24.1) 5 (21.7)
Central necrotic zone 0.877
    No  123 (93.2) 51 (92.7) 11 (100.0) 7 (87.5) 6 (100.0) 27 (93.1) 21 (91.3)
    Yes  9 (6.8) 4 (7.3) 0 (0.0) 1 (12.5) 0 (0.0) 2 (6.9) 2 (8.7)
Central fibrotic zone 0.351
    No  106 (80.3) 41 (74.5) 11 (100.0) 6 (75.0) 6 (100.0) 23 (79.3) 19 (82.6)
    Yes  26 (19.7) 14 (25.5) 0 (0.0) 2 (25.0) 0 (0.0) 6 (20.7) 4 (17.4)
Lymphocytic infiltration 0.025
    Absent 99 (75.0) 41 (74.5) 8 (72.7) 7 (87.5) 2 (33.3) 19 (65.5) 22 (95.7)
    Present 33 (25.0) 14 (25.5) 3 (27.3) 1 (12.5) 4 (66.7) 10 (34.5) 1 (4.3)
Tumor cell discohesiveness 0.082
    No  122 (92.4) 53 (96.4) 8 (72.7) 7 (87.5) 6 (100.0) 28 (96.6) 20 (87.0)
    Yes  10 (7.6) 2 (3.6) 3 (27.3) 1 (12.5) 0 (0.0) 1 (3.4) 3 (13.0)
Tumor margin   0.165
    Expanding 112 (84.8) 49 (89.1) 8 (72.7) 7 (87.5) 6 (100.0) 26 (89.7) 16 (69.6)
    Infiltrative 20 (15.2) 6 (10.9) 3 (27.3) 1 (12.5) 0 (0.0) 3 (10.3) 7 (30.4)
Apocrine differentiation 0.026
    No  108 (81.8) 47 (85.5) 5 (45.5) 7 (87.5) 4 (66.7) 24 (82.8) 21 (91.3)
    Yes  24 (18.2) 8 (14.5) 6 (54.5) 1 (12.5) 2 (33.3) 5 (17.2) 2 (8.7)
    Ki 67 LI (%, mean ± SD) 27.3±23.3 33.3±24.6 6.0±4.8 27.3±27.8 38.6±27.5 28.5±22.4 20.7±17.4 0.005
    Tumor recurrence 14 (10.6) 7 (12.7) 1 (9.1) 1 (12.5) 0 (0.0) 1 (3.4) 4 (17.4) 0.591
    Patient death 14 (10.6) 7 (12.7) 1 (9.1) 1 (12.5) 1 (16.7) 0 (0.0) 4 (17.4) 0.403
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the application of the Bonferroni multiple com-
parison procedure was used. Statistical signifi-
cance was set to P<0.05. Kaplan-Meier survival 
curves and log-rank statistics were employed 
to evaluate time to tumor recurrence and over-
all survival. Multivariate regression analysis 
was performed using the Cox proportional haz-
ards model.
Results 
Basal characteristics of breast cancer 
In 230 breast cancers, 115 (50.0%), 57 
(24.8%), 15 (6.5%), and 43 (18.7%) were of 
luminal A, luminal B, HER-2 and TNBC subtype, 
respectively. TNBC subtype had higher histo-
logical grade (P<0.001), higher Ki-67 LI 
(P<0.001) compared to other subtypes. The 
stromal types were different according to 
molecular subtypes (P=0.007), with higher pro-
portion of lymphocytic type in TNBC subtype, 
higher rate of desmoplastic type in luminal B 
subtype and higher rate of sclerotic type in 
other molecular subtypes (Table 2).
Expression of BRAF V600E mutation specific 
antibody in breast cancer
The immunohistochemical expression of BRAF 
V600E mutation specific antibody was investi-
gated in breast cancers. Thirty (13.0%) cases 
showed cytoplasmic expression, 17 (7.4%) 
showed nuclear expression (Figure 1). On an 
analysis of correlation between the clinicopath-
ologic parameters and BRAF V600E status, 
cytoplasmic BRAF V600E status did not show 
an association with clinicopathologic parame-
ters. On the other hand, nuclear BRAF V600E 
status was associated with ER negativity 
(P=0.003), PR negativity (P=0.031) and TNBC 
molecular subtype (P=0.009) (Table 3).
Basal characteristics of TNBC
In 132 TNBC cases, 55 (41.7%), 11 (8.3%), 8 
(6.1%), 6 (4.6%), 29 (22.0%), and 23 (17.4%) 
Figure 2. Representative positive cases for BRAF V600E mutation specific antibody in triple negative breast cancer.
BRAF V600E mutation in breast cancer
1552 Int J Clin Exp Pathol 2016;9(2):1545-1556
were of basal-like type, molecular apocrine 
type, claudin low type, immune related type, 
mixed type and null type, respectively. 
Lymphocytic infiltration was most frequently 
found in immune related type (P=0.025), and 
molecular apocrine type was associated with 
apocrine differentiation (P=0.026) and lower 
Ki-67 LI (P=0.005) (Table 4). 
Expression of BRAF V600E mutation specific 
antibody in TNBC
In an analysis of immunohistochemical expres-
sion of BRAF V600E mutation specific antibody 
with TNBC, 4 (3.0%) showed cytoplasmic 
expression (Figure 2) and 10 (7.6%) showed 
nuclear expression. The rate of cytoplasmic 
BRAF V600E positivity was highest in null type 
and followed by mixed type and basal-like type, 
and it was not found in other types of TNBC. 
The rate of nuclear BRAF V600E positivity was 
highest in molecular apocrine 
type, followed by mixed type, 
claudin low type, null type and 
basal-like type, and BRAF 
V600E positive case was not 
found in immune related type 
(Table 5). The correlation 
between BRAF V600E status 
and clinicopathologic parame-
ters was analyzed. The cyto-
plasmic BRAF V600E status 
was not associated with clini-
copathologic parameters, but 
the nuclear BRAF V600E sta-
tus was associated with histo-
logical grade (P=0.012). The 
nuclear BRAF V600E positivity 
was associated with lower his-
tologic grade (Figure 3).
Impact of BRAF V600E status 
Table 5. Clinicopathologic characteristics of patients according to triple negative breast cancer sub-
type





















    Negative 128 (97.0) 54 (98.2) 11 (100.0) 8 (100.0) 6 (100.0) 28 (96.6) 21 (91.3)
    Positive 4 (3.0) 1 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.4) 2 (8.7)
Nuclear BRAF V600E 0.337
    Negative 122 (92.4) 53 (96.4) 9 (81.8) 7 (87.5) 6 (100.0) 25 (86.2) 22 (95.7)
    Positive 10 (7.6) 2 (3.6) 2 (18.2) 1 (12.5) 0 (0.0) 4 (13.8) 1 (4.3)
Figure 3. Correlation between BRAF V600E status and clinicopathologic pa-
rameters in triple negative breast cancer.
in patient prognosis
A univariate analysis was performed to evalu-
ate the impact of BRAF V600E status on the 
prognosis of breast cancer and TNBC. The cyto-
plasmic and nuclear BRAF V600E status did 
not correlate with shorter disease free survival 
or overall survival (Table 6).
Discussion
In this study, we investigated the BRAF muta-
tion status in breast cancer using IHC with 
BRAF V600E mutation specific antibody, and 
13% of breast cancer and 3% of TNBC showed 
positivity for BRAF V600E mutation specific 
antibody. The gold standard method for the 
detection of BRAF mutation is Sanger sequenc-
ing analysis, and other PCR-based methods 
such as single-strand conformation polymor-
phism, restriction fragment length polymor-
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phism (RFLP), mass-array spectrometry, pyro-
sequencing, and mutation-specific PCR have 
been also proposed. But these methods require 
expensive equipment, high technical skills, and 
have other problems such as tissue heteroge-
neity, sampling error, suboptimal DNA preser-
vation of formalin-fixed paraffin-embedded 
(FFPE) tissue. These drawbacks limited its gen-
eral use in clinical fields [18]. To overcome 
the abovementioned limitations, novel mouse 
monoclonal mutation-specific anti-BRAFV600E 
antibody was developed [6], and it is reported 
to be very useful in detecting BRAF mutation in 
various neoplasms [7, 16, 19-21]. Especially in 
comparison studies using FFPE tissue, the IHC 
method using BRAF V600E mutation specific 
antibody was reported to be more specific and 
more sensitive compared to Sanger sequenc-
ing method, suggesting that IHC by BRAF 
V600E mutation specific antibody could be a 
new golden standard method [16]. Therefore 
our results of positive IHC staining of BRAF 
V600E mutation suggest that BRAF mutation is 
found in a proportion of breast cancers. In pre-
vious studies using sequencing methods, it is 
reported that 10% of breast cancer cell lines 
harbored BRAF mutation [9], 3% of breast can-
cer tissue (IDC) had BRAF mutation, and BRAF 
mutation was found in 2.6% in TNBC. In our 
study, a similar rate of BRAF positivity with the 
previous study regarding TNBC was noted, but 
in IDC, our study showed a bit higher rate of 
BRAF mutation compared to the previous study 
regarding IDC.
In previous studies regarding thyroid cancer tis-
sues, the expression was reported to be diffuse 
and homogenous in positive cases in general 
[16, 22], and the result of our study with breast 
cancer also showed diffuse and homogenous 
positive staining pattern, which is consistent 
with previous studies. In this study, the nuclear 
expression to BRAF V600E mutation specific 
antibody was found in 8.0% of IDC and 7.6% of 
TNBC. In previous studies regarding the expres-
sion of BRAF V600E mutation specific antibody 
in other neoplasms, only cytoplasmic expres-
sions are reported [7, 16, 19-22]. In this study, 
the aberrant nuclear expression for BRAF 
V600E antibody of breast cancer was associ-
ated with clinicopathologic factors such as ER 
negativity (P=0.003), PR negativity (P=0.031) 
and TNBC subtype (P=0.009), and it needs to 
be further evaluated in future studies. On the 
contrary, the BRAF V600E mutation status did 
not have association with clinicopathologic fac-
tors. In previous studies, BRAF mutation is 
reported to be associated with several clinico-
pathologic features related to prognosis, such 
as lymph node metastasis and distant metas-
tasis in PTC [23], younger age and tumor occur-
rence from intermittently sun-exposed skin in 
Table 6. Univariate analysis of the impact of expression in breast cancer on disease-free and overall 
survival by the log-rank test
Parameter Number of patients/recurrence/death 
Disease-free survival Overall survival
Mean survival 
(95% CI) months P-value
Mean survival  
(95% CI) months P-value
Breast cancer patients group
    BRAF V600E N/A 0.342
        Negative 200/11/17 N/A 64 (63-66)
        Positive 30/0/1 N/A 67 (64-70)
    Nuclear BRAF V600E 0.776 0.817
        Negative 213/10/17 66 (65-68) 66 (64-67)
        Positive 17/1/1 65 (63-66) 63 (59-68)
TNBC patients group
    BRAF V600E N/A N/A
        Negative 128/14/14 N/A N/A
        Positive 4/0/0 N/A N/A
    Nuclear BRAF V600E N/A 0.987
        Negative 122/14/13 N/A 93 (88-98)
        Positive 10/0/1 N/A 69 (60-78)
Note: TNBC, triple negative breast cancer.
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malignant melanoma [24, 25], poor prognosis 
in colon cancer [26, 27], which are different 
from the result from our study regarding breast 
cancer. In non-small cell lung cancer, BRAF 
mutation status was not associated with clini-
cal outcome [28] like the result of our study 
with breast cancer.
The clinical implication of this study is the 
potential use of BRAF mutation status for the 
application of targeted therapy. In various neo-
plasms including malignant melanoma, drugs 
targeting BRAF mutation (vemurafenib and 
dabrafenib) is already in use in preclinical and 
clinical phase [29-31], so targeted therapy in 
breast cancers with BRAF mutation can also be 
considered. Especially in TNBC, which is a small 
proportion of breast cancer but does not have 
any effective therapeutic agent except surgery, 
BRAF mutation targeted therapy can be a pos-
sible treatment, and a further study is needed. 
In conclusion, a proportion of breast cancer 
and TNBC showed positivity for the IHC by BRAF 
V600E mutation specific antibody, suggesting 
BRAF mutation, and BRAF mutation did 
not show association with clinicopathologic 
factors.
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